Skip to content

Dianthus Therapeutics DNTH Alliance revenues

Alliance revenues at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$94M+6.8%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$321M+1.9%
Cencora logo
CencoraCOR
$6.52B+12.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.9B+24.1%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$3.5M-60.7%
Eli Lilly logo
Eli LillyLLY
$1.35B+19.4%

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$4.51B+662%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×